Targeting IL-12 and IL-23 in immune-related adverse events from checkpoint inhibitors: current evidence and future directions
- DOI
- 10.1016/j.ejca.2026.117788
- Published
- 2026-12
- Container
- European Journal of Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2026.117788,
title = {Targeting IL-12 and IL-23 in immune-related adverse events from checkpoint inhibitors: current evidence and future directions},
author = {Malek Shatila and David Farris and Pankti Reid and Thomas U. Marron and Sophia C. Weinmann and Alexa S. Meara and Yinghong Wang},
year = {2026},
journal = {European Journal of Cancer},
doi = {10.1016/j.ejca.2026.117788},
url = {https://doi.org/10.1016/j.ejca.2026.117788}
}RIS
TY - JOUR TI - Targeting IL-12 and IL-23 in immune-related adverse events from checkpoint inhibitors: current evidence and future directions AU - Malek Shatila AU - David Farris AU - Pankti Reid AU - Thomas U. Marron AU - Sophia C. Weinmann AU - Alexa S. Meara AU - Yinghong Wang PY - 2026 JO - European Journal of Cancer DO - 10.1016/j.ejca.2026.117788 UR - https://doi.org/10.1016/j.ejca.2026.117788 ER -
APA
Shatila, M., Farris, D., Reid, P., Marron, T. U., Weinmann, S. C., Meara, A. S., & Wang, Y. (2026). Targeting IL-12 and IL-23 in immune-related adverse events from checkpoint inhibitors: current evidence and future directions. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117788
Source records
- crossref · retrieved 2026-11-09T07:53:33.996Z